Momelotinib in myelofibrosis

References

• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057–1069. doi: 10.1038/s41375-018-0077-1 Epub 2018 Feb 27. PMID: 29515238; PMCID: PMC5986069.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z PMID: 28228106; PMCID: PMC5322633.
   PubMedGoogle Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 Aug;30(8):1701–1707. doi: 10.1038/leu.2016.148 Epub 2016 May 23. Erratum in: Leukemia. 2017 Mar;31(3):775. PMID: 27211272; PMCID: PMC5399157.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A, Masszi T, et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol. 2021 Oct;195(2):244–248. doi: 10.1111/bjh.17727 Epub 2021 Jul 30. PMID: 34331348; PMCID: PMC9292894.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomized, phase 2, multicentre study. Lancet Haematol. 2017 Jul;4(7):e317–e324. doi: 10.1016/S2352-3026(17)30088-1 Epub 2017 Jun 8. PMID: 28602585; PMCID: PMC8207822.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009 Mar 26;113(13):2895–2901. doi: 10.1182/blood-2008-07-170449 Epub 2008 Nov 6. PMID: 18988864.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment). Blood. 2010 Mar 4;115(9):1703–1708. doi: 10.1182/blood-2009-09-245837 Epub 2009 Dec 14. PMID: 20008785.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1;29(4): 392–397. doi: 10.1200/JCO.2010.32.2446 Epub 2010 Dec 13. PMID: 21149668.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014 Jul;28(7):1494–1500. doi: 10.1038/leu.2014.57 Epub 2014 Feb 5. PMID: 24496303.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012 Jan;87(1):25–33. doi: 10.1016/j.mayocp.2011.11.001 PMID: 22212965; PMCID: PMC3538387.
   PubMed Web of Science ®Google Scholar
• Scherber RM, Mesa RA. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. Blood Rev. 2020; Jul;42:100716. doi: 10.1016/j.blre.2020.100716 Epub 2020 May 30. PMID: 32593470; PMCID: PMC8895349.
   PubMed Web of Science ®Google Scholar
• Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016 Dec;101(12):e482–e484. doi: 10.3324/haematol.2016.151449 Epub 2016 Sep 1. PMID: 27587385; PMCID: PMC5479619.
   PubMed Web of Science ®Google Scholar
• Kuykendall AT, Shah S, Talati C, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar;97(3):435–441. doi: 10.1007/s00277-017-3194-4 Epub 2017 Nov 30. PMID: 29189896.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Mehra M, He J, et al. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. J Med Econ. 2020 Jul;23(7):721–727. doi: 10.1080/13696998.2020.1741381 Epub 2020 Mar 31. PMID: 32159402.
   PubMed Web of Science ®Google Scholar
• Daver N, Cortes J. Newberry K et alRuxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug;100(8):1058–1063. doi: 10.3324/haematol.2015.126821 Epub 2015 Jun 18. PMID: 26088933; PMCID: PMC5004422.
   PubMed Web of Science ®Google Scholar
• Gowin K, Kosiorek H, Dueck A, et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res. 2017 Sep;60:31–35. doi: 10.1016/j.leukres.2017.06.005 Epub 2017 Jun 13. PMID: 28646676.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 1;101(7):2534–2541. doi: 10.1182/blood-2002-09-2928 Epub 2002 Nov 27. PMID: 12517815.
   PubMed Web of Science ®Google Scholar
• Luo X, Xu Z, Li B, et al. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J. 2018 Jan 15;8(1): 9. doi: 10.1038/s41408-017-0029-4 PMID: 29335406; PMCID: PMC5802625.
   PubMedGoogle Scholar
• Hernández-Boluda JC, Correa JG, García-Delgado R, et al. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol. 2017 Apr;98(4):407–414. doi: 10.1111/ejh.12846 Epub 2017 Jan 19. PMID: 28009442.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018 May 1;4(5):652–659. doi: 10.1001/jamaoncol.2017.5818 PMID: 29522138; PMCID: PMC5885169.
   PubMed Web of Science ®Google Scholar
• Oh ST, Mesa RA, Harrison CN, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 Oct 10;7(19): 5835–5842. doi: 10.1182/bloodadvances.2023010151 PMID: 37552106; PMCID: PMC10561048.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou H, Duan M, et al. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023 Oct;98(10):1588–1597. doi: 10.1002/ajh.27033 Epub 2023 Jul 20. PMID: 37470365.
   PubMed Web of Science ®Google Scholar
• Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017 Mar 30;129(13):1823–1830. doi: 10.1182/blood-2016-09-740092 Epub 2017 Feb 10. PMID: 28188131; PMCID: PMC5693322.
   PubMed Web of Science ®Google Scholar
• Yadin D, Knaus P, Mueller TD. Structural insights into BMP receptors: Specificity, activation and inhibition. Cytokine Growth Factor Rev. 2016; Feb;27:13–34. doi: 10.1016/j.cytogfr.2015.11.005 Epub 2015 Nov 24. PMID: 26690041.
   PubMed Web of Science ®Google Scholar
• Li J, Tang X, Chen X. Comparative effects of TGF-β2/Smad2 and TGF-β2/Smad3 signaling pathways on proliferation, migration, and extracellular matrix production in a human lens cell line. Exp Eye Res. 2011 Mar;92(3):173–179. doi: 10.1016/j.exer.2011.01.009 Epub 2011 Jan 27. PMID: 21276793.
   PubMed Web of Science ®Google Scholar
• Barruet E, Morales BM, Lwin W, et al. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther. 2016 Aug 17;7(1):115. doi: 10.1186/s13287-016-0372-6 PMID: 27530160; PMCID: PMC4988052.
   PubMedGoogle Scholar
• Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020 Jan 31;105(2):260–272. doi: 10.3324/haematol.2019.232124 PMID: 31949017; PMCID: PMC7012465.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Finke C, Abdelrahman RA, et al. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013 Apr;88(4):312–316. doi: 10.1002/ajh.23406 Epub 2013 Feb 28. PMID: 23450619.
   PubMed Web of Science ®Google Scholar
• Zhou A, Kong T, Fowles JS, et al. Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. Br J Haematol. 2022 May;197(4):e49–e52. doi: 10.1111/bjh.18044 Epub 2022 Feb 6. PMID: 35128632.
   PubMed Web of Science ®Google Scholar
• Gupta V, Mesa RA, Deininger MW, et al. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017 Jan;102(1):94–102. doi: 10.3324/haematol.2016.148924 Epub 2016 Sep 15. PMID: 27634203; PMCID: PMC5210237.
   PubMed Web of Science ®Google Scholar
• Oh ST, Talpaz M, Gerds AT, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020 Sep 22;4(18): 4282–4291. doi: 10.1182/bloodadvances.2020002662 PMID: 32915978; PMCID: PMC7509854.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barraco D, Lasho TL, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018 Mar 7;8(3): 29. doi: 10.1038/s41408-018-0067-6 PMID: 29515114; PMCID: PMC5841331.
   PubMedGoogle Scholar
• Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: A Phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844–3850. doi: 10.1200/JCO.2017.73.4418 Epub 2017 Sep 20. PMID: 28930494; PMCID: PMC6553796.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Platzbecker U, Mayer J, et al. Improved transfusion independence rates for momelotinib vs ruxolitinib in anemic JAKi-nave myelofibrosis patients independent of baseline platelet or transfusion status. Hemasphere. 2021;5(S2).
   Google Scholar
• Oh ST, Verstovsek S, Gupta V, et al. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem. 2024 Feb 5;5(1): 105–116. doi: 10.1002/jha2.854 PMID: 38406514; PMCID: PMC10887367.
   PubMedGoogle Scholar
• Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb;5(2):e73–e81. Epub 2017 Dec 20. doi:10.1016/S2352-3026(17)30237-5 PMID: 29275119.
   PubMed Web of Science ®Google Scholar
• Mesa R, Harrison C, Oh ST, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022 Sep;36(9):2261–2268. doi: 10.1038/s41375-022-01637-7 Epub 2022 Jul 22. PMID: 35869266; PMCID: PMC9417985.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023 Jan 28;401(10373):269–280. doi: 10.1016/S0140-6736(22)02036-0 Erratum in: Lancet. 2023 Apr 29;401(10386):1426. Erratum in: Lancet. 2023 Dec 9;402(10418):2196. PMID: 36709073.
   PubMed Web of Science ®Google Scholar
• Masarova L, Versotovsek S, Palandri F, et al. Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF). JCO. 2023;41(16_suppl):7065–7065. doi: 10.1200/JCO.2023.41.16_suppl.7065
   Web of Science ®Google Scholar
• Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. Hemasphere. 2017 Dec 20;1(1):e1. doi: 10.1097/HS9.0000000000000001 PMID: 31723730; PMCID: PMC6745971.
   PubMed Web of Science ®Google Scholar
• Fisher DAC, Malkova O, Engle EK, et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017 Sep;31(9):1962–1974. doi: 10.1038/leu.2016.377 Epub 2016 Dec 23. PMID: 28008177; PMCID: PMC5540814.
   PubMed Web of Science ®Google Scholar
• Dunbar AJ, Kim D, Lu M, et al. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023 May 18;141(20): 2508–2519. doi: 10.1182/blood.2022015418 PMID: 36800567; PMCID: PMC10273167.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL- 2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–1363. doi: 10.1200/JCO.2010.32.9490
   PubMed Web of Science ®Google Scholar
• Gangat N, Begna KH, Al-Kali A, et al. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023 Jan 4;13(1):3. doi: 10.1038/s41408-022-00780-9 PMID: 36599841; PMCIDPMC9813003.
   PubMed Web of Science ®Google Scholar
• Bruzzese A, Martino EA, Mendicino F, et al. Iron chelation therapy. Eur J Haematol. 2023 May;110(5):490–497. doi: 10.1111/ejh.13935 Epub 2023 Feb 8. PMID: 36708354.Pullarkat V. Improving erythropoiesis: a compelling case for iron chelation in myelofibrosis. Eur J Haematol. 2016 Jun;96(6):549-50. doi: 10.1111/ejh.12702 PMID: 26572646.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013 Aug 22;122(8):1395–1398. doi: 10.1182/blood-2013-03-488098 Epub 2013 Jul 9. PMID: 23838352; PMCID: PMC4828070.
   PubMed Web of Science ®Google Scholar
• Groepper S, Schlue J, Haferlach C, et al. Transfusion independence and histological remission in a patient with advanced primary myelofibrosis receiving iron-chelation therapy with deferasirox. Oncol Res Treat. 2016;39(6):384–387. doi: 10.1159/000446029 Epub 2016 May 25. PMID: 27260366.
   PubMed Web of Science ®Google Scholar
• Leitch HA, Chase JM, Goodman TA, et al. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010 Mar;28(1):40–48 doi: 10.1002/hon.902. PMID: 19557769.
   PubMed Web of Science ®Google Scholar
• Carreau N, Tremblay D, Savona M, et al. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Rev. 2016 Sep;30(5):349–356. doi: 10.1016/j.blre.2016.04.003 Epub 2016 Apr 20. PMID: 27106071.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020 Jan 9;382(2):140–151. doi: 10.1056/NEJMoa1908892 PMID: 31914241.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Viprakasit V, Taher AT, et al. A Phase 3 Trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020 Mar 26;382(13):1219–1231. doi: 10.1056/NEJMoa1910182 PMID: 32212518.
   PubMed Web of Science ®Google Scholar
• Bruzzese A, Vigna E, Martino EA, et al. Myelodysplastic syndromes with ring sideroblasts. Hematol Oncol. 2023 Oct;41(4):612–620. doi: 10.1002/hon.3125 Epub 2023 Feb 26. PMID: 36794650.
   PubMed Web of Science ®Google Scholar
• Azhar M, Kincaid Z, Kesarwani M, et al. Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Adv. 2022 Feb 22;6(4): 1186–1192. doi: 10.1182/bloodadvances.2021004611 2021004611. PMID: 34768286; PMCID: PMC8864657.
   PubMed Web of Science ®Google Scholar